An interactive Whistle-to-Music composing system based on transcription, variation and chords generation

Hung-Che Shen,Chungnan Lee

DOI: https://doi.org/10.1007/s11042-010-0510-6

IF: 2.577

2011-05-01

Multimedia Tools and Applications

Abstract:

What problem does this paper attempt to address?

Proteome and phosphoproteome reveal mechanisms of action of atorvastatin against esophageal squamous cell carcinoma

Qiang Yuan,Christopher D Dong,Yang Ge,Xinhuan Chen,Zhenzhen Li,Xin Li,Qiqi Lu,Feng Peng,Xiangyu Wu,Jimin Zhao,Kangdong Liu,Christopher D. Dong

DOI: https://doi.org/10.18632/aging.102402

2019-11-07

Aging

Abstract:Statins comprise a class of prescription drugs used for reducing cholesterol. Evidence has also showed that statins could reduce cancer incidence. However, the anti-tumor mechanism of statins has not been fully defined. Here, we found that atorvastatin inhibited proliferation of esophageal squamous cell carcinoma (ESCC) cells. The underlying mechanisms were explored by mass spectrometry. The proteome data revealed that atorvastatin inhibited the cAMP and Rap1 signal pathways, except for Ras signal pathway. Interestingly, phosphoproteome profiles suggested that ERKT185/Y187, CDK1T14, and BRAC1S1189 phosphorylation-mediated Th17 cell differentiation, Gap junction and the Platinum drug resistance pathway were down-regulated after atorvastatin treatment. The phosphorylation levels of ERKT185/Y187, CDK1T14 and BRAC1S1189 were confirmed by western blotting in KYSE150 cells. More importantly, atorvastatin suppresses ESCC tumor growth in PDX models. The molecular changes in tumor tissues were confirmed by immunohistochemistry. In conclusion, deep-proteome and phosphoproteome analysis reveal a comprehensive mechanism that contributes to atorvastatin's anti-tumor effect.
Cloperastine inhibits esophageal squamous cell carcinoma proliferation in vivo and in vitro by suppressing mitochondrial oxidative phosphorylation

Bo Li,Yin Yu,Yanan Jiang,Lili Zhao,Ang Li,Mingzhu Li,Baoyin Yuan,Jing Lu,Ziming Dong,Jimin Zhao,Kangdong Liu

DOI: https://doi.org/10.1038/s41420-021-00509-w

2021-06-01

Cell Death Discovery

Abstract:Abstract Esophageal squamous cell carcinoma (ESCC) is a major type of esophageal cancer. The prognosis of patients with ESCC remains poor because of the high morbidity and mortality of the disease. One strategy for drug discovery for ESCC treatment or prevention is screening FDA-approved drugs. In the present study, we found that the antitussive agent cloperastine can inhibit the proliferation of ESCC cells. However, the underlying mechanism was unclear. To determine the mechanism of this inhibitory effect, we performed proteomic analysis using KYSE150 cells treated with cloperastine and DMSO. The results identified several down-regulated signaling pathways included those of three key proteins (NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 1, NADH ubiquinone oxidoreductase subunit S5, and cytochrome C oxidase subunit 6B1) involved in oxidative phosphorylation. Meanwhile, we observed that oxidative phosphorylation in mitochondria was inhibited by the drug. Importantly, cloperastine suppressed ESCC growth in a xenograft mouse model in vivo. Our findings revealed that cloperastine inhibits the proliferation of ESCC in vivo and in vitro by suppressing mitochondrial oxidative phosphorylation.

cell biology
Proteomics Reveal the Inhibitory Mechanism of Levodopa Against Esophageal Squamous Cell Carcinoma

Zhenzhen Li,Xin Li,Xinyu He,Xuechao Jia,Xiaofan Zhang,Bingbing Lu,Jimin Zhao,Jing Lu,Lexia Chen,Ziming Dong,Kangdong Liu,Zigang Dong

DOI: https://doi.org/10.3389/fphar.2020.568459

IF: 5.6

2020-09-25

Frontiers in Pharmacology

Abstract:High recurrence rates and poor survival of patients with esophageal squamous cell carcinoma (ESCC) after treatment make ongoing research on chemoprevention drugs for ESCC particularly important. In this study, we screened a large number of FDA-approved drugs and found levodopa, a drug used to treat Parkinson's disease, had an inhibitory effect on the growth of ESCC cells. To elucidate the molecular mechanisms involved, we applied quantitative proteomics to investigate the anti-tumor activity of levodopa on ESCC. The results suggest that levodopa could down-regulate oxidative phosphorylation, non-alcoholic fatty liver disease, and Parkinson's disease pathways. Major mitochondrial respiratory compounds were involved in the pathways, including succinate dehydrogenase subunit D, NADH-ubiquinone oxidoreductase Fe-S protein 4, and mitochondrial cytochrome c oxidase subunit 3. Down-regulation of these proteins was associated with mitochondrial dysfunction. Western blotting and immunofluorescence results confirmed the proteomics findings. Cell viability assays indicated mitochondrial activity was suppressed after levodopa treatment. Reduced mitochondrial membrane potential was detected using JC-1 staining and TMRE assays. Transmission electron microscopy revealed changes in the morphology of mitochondria. Taken together, these results indicate that levodopa inhibited the growth of ESCC through restraining mitochondria function.

pharmacology & pharmacy
Lovastatin-mediated Pharmacological Inhibition of Formin Protein DIAPH1 Suppresses Tumor Immune Escape and Boosts Immunotherapy Response

Mengyun Wan,Ji Zhou,Ningyi Xue,Jie Mei,Jiaofeng Zhou,Xinyu Zong,Junli Ding,Qing Li,Zhicheng He,Yichao Zhu

DOI: https://doi.org/10.1016/j.intimp.2024.113637

IF: 5.714

2024-01-01

International Immunopharmacology

Abstract:BACKGROUND:The immunosuppressive tumor microenvironment (TME) is a key characteristic of human cancer. Immunotherapy has emerged as a promising treatment strategy to overcome immune escape and has gained widespread use in recent years. In particular, the blockade of PD-1/PD-L1 interaction holds significant importance in oncotherapy. Combining anti-PD-1/PD-L1 with small molecule inhibitors targeting key pathways represents an emerging trend in therapeutic development. METHODS:To validate our findings biologically, we employed qRT-PCR or Western blotting and immunofluorescence staining techniques to assess the expression levels of DIAPH1 and PD-L1 in cells. Additionally, CCK8 and clone formation assays were utilized to evaluate cell proliferation ability, while flow assays were conducted to detect apoptosis in T cells. RESULTS:Knockdown of DIAPH1 restored the tumor-killing capacity of T cells, effectively suppressing tumor immune escape. We observed a highly positive correlation between the expression levels of DIAPH1 and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), which can be competitively inhibited by lovastatin. Through Sybyl analysis followed by confirmation via micro scale thermophoresis, we identified lovastatin as a potential inhibitor targeting DIAPH1. Lovastatin downregulated DIAPH1 expression both in tumor cell lines and xenograft lung cancer tissues within a mouse lung cancer model. Furthermore, we found that lovastatin degraded DIAPH1 through lysosomal degradation pathway. Treatment with lovastatin was strongly associated with improved response rates and prolonged overall survival among patients with lung adenocarcinoma. Finally, overexpression of DIAPH1 reversed the inhibitory effects mediated by lovastatin on tumor development. CONCLUSIONS:Lovastatin downregulates PD-L1 expression by targeting DIAPH1 and restores the tumor-killing ability of T cells to block tumor immune escape. Lovastatin may become a potential drug for cancer patients to enhance immunotherapy response in the clinic.
Protection of Functional and Vascular Integrity of the Spleen in Traumatic Shock by Denervation.∗

B. Zetterstrom,C. Palmerio,J. Fine

DOI: https://doi.org/10.3181/00379727-117-29584

1964-11-01

Abstract:Summary In dogs with part of the spleen denervated, the morphologic and functional injury that shock inflicts is restricted to the non-denervated part of the spleen. The de-nervated part escapes injury because denervation prevents release of norepinephrine from its stores. It is the norepinephrine released in the innervated tissue that accounts for the injury to this tissue, including its vascular muscle, and hence for the progressive failure of the circulation of the non-denervated animal. The circulating catecholamines do not play a significant role in production of this injury or in the vascular collapse and death.
Metformin Inhibited Esophageal Squamous Cell Carcinoma Proliferation in Vitro and in Vivo and Enhanced the Anti-Cancer Effect of Cisplatin

Feng Wang,Xianfei Ding,Tao Wang,Zhengzheng Shan,Jun Wang,Shaoxuan Wu,Yanyan Chi,Yana Zhang,Zhuan Lv,Liuxing Wang,Qingxia Fan

DOI: https://doi.org/10.1371/journal.pone.0174276

IF: 3.7

2017-01-01

PLoS ONE

Abstract:Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with poor prognosis in China. Chemotherapy now is one of the most frequently used treatments for patients with ESCC in middle or late stage, however the effects were often limited by increased chemoresistance or treatment toxicity. So it is urgent to find new drugs to treat ESCC patients. Metformin with low cost and toxicity has proved to have anti-cancer effects in a numerous cancers, while its role and mechanism in ESCC has seldom been studied. In the present study, we found that metformin exhibited not only an anti-proliferation ability in a dose and time dependent manner but also a proapoptosis effect in a dose dependent manner in ESCC cell line KYSE450. Our in vivo experiment also showed that metformin markedly inhibited KYSE450 xenograft tumors growth compared to those treated with normal saline. What’s more, no obvious toxic reactions were observed. To further explore the underlying mechanism, we found that metformin treatment could significantly damp the expression of 4EBP1 and S6K1 in KYSE 450 cells in vitro and in vivo, furthermore, the p-4EBP1 and p-S6K1 expression in KYSE 450 cells were also inhibited greatly in vitro and in vivo. During the therapy of cancer, in order to overcome side effects, combination therapy was often used. In this paper, we demonstrated that metformin potentiated the effects of cisplatin via inhibiting cell proliferation and promoting cell apoptosis. Taken together, metformin owned the potential anti-cancer effect on ESCC in monotherapy or was combined with cisplatin and these results laid solid basis for the use of metformin in ESCC.
Dysregulated Ribosome Biogenesis is a Targetable Vulnerability in Triple-Negative Breast Cancer: MRPS27 As a Key Mediator of the Stemness-inhibitory Effect of Lovastatin

Chanjuan Zheng,Hui Yao,Lu,Hongqi Li,Lei Zhou,Xueyan He,Xi Xu,Hongzhuo Xia,Siyu Ding,Yiyuan Yang,Xinyu Wang,Muyao Wu,Lian Xue,Sisi Chen,Xiaojun Peng,Zhongyi Cheng,Yian Wang,Guangchun He,Shujun Fu,Evan T. Keller,Suling Liu,Yi-zhou Jiang,Xiyun Deng

DOI: https://doi.org/10.7150/ijbs.94058

2024-01-01

International Journal of Biological Sciences

Abstract:Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with limited effective therapeutic options readily available. We have previously demonstrated that lovastatin, an FDA-approved lipid-lowering drug, selectively inhibits the stemness properties of TNBC. However, the intracellular targets of lovastatin in TNBC remain largely unknown. Here, we unexpectedly uncovered ribosome biogenesis as the predominant pathway targeted by lovastatin in TNBC. Lovastatin induced the translocation of ribosome biogenesis-related proteins including nucleophosmin (NPM), nucleolar and coiled-body phosphoprotein 1 (NOLC1), and the ribosomal protein RPL3. Lovastatin also suppressed the transcript levels of rRNAs and increased the nuclear protein level and transcriptional activity of p53, a master mediator of nucleolar stress. A prognostic model generated from 10 ribosome biogenesis-related genes showed outstanding performance in predicting the survival of TNBC patients. Mitochondrial ribosomal protein S27 (MRPS27), the top-ranked risky model gene, was highly expressed and correlated with tumor stage and lymph node involvement in TNBC. Mechanistically, MRPS27 knockdown inhibited the stemness properties and the malignant phenotypes of TNBC. Overexpression of MRPS27 attenuated the stemness-inhibitory effect of lovastatin in TNBC cells. Our findings reveal that dysregulated ribosome biogenesis is a targetable vulnerability and targeting MRPS27 could be a novel therapeutic strategy for TNBC patients.
The Combination of Two Bioactive Constituents, Lactoferrin and Linolenic Acid, Inhibits Mouse Xenograft Esophageal Tumor Growth by Downregulating Lithocholyltaurine and Inhibiting the JAK2/STAT3-Related Pathway

Huiying Li,Qianqian Yao,Li Min,Shengnan Huang,Haoming Wu,Huaigu Yang,Linlin Fan,Jiaqi Wang,Nan Zheng

DOI: https://doi.org/10.1021/acsomega.0c01132

IF: 4.1

2020-08-11

ACS Omega

Abstract:The addition of lactoferrin and three unsaturated fatty acids, oleic acid, docosahexaenoic acid (DHA), and linolenic acid, to dairy products was approved in recent years. Research into the biological activities of lactoferrin and these three unsaturated fatty acids has revealed anti-inflammatory, antiviral, antioxidant, antitumor, antiparasitic, and antibiotic effects. However, investigations and comparisons of lactoferrin + oleic acid/DHA/linolenic acid combinations in an esophageal cancer cell model and in xenograft tumor models have not been extensively reported, and the related mechanism of these combinations remains elusive. In the present study, the effects of lactoferrin and the three fatty acids on KYSE450 cell viability, migration, and invasion were investigated to choose the proper doses and effective combination in vitro. A tumor-bearing nude mouse model was established to investigate the role of selected combinations in inhibiting esophageal tumor formation in vivo. Metabonomics detection and data analysis were performed to screen special metabolites and related pathways, which were validated by western blotting. The results demonstrated that lactoferrin, the three unsaturated fatty acids, and their combinations inhibited the viability, migration, and invasion of KYSE450 cells and induced apoptosis and the lactoferrin + linolenic acid combination exhibited the strongest activity in suppressing KYSE450 tumor formation in vivo. The lactoferrin + linolenic acid combination inhibited phosphorylation in the JAK2/STAT3-related pathway by downregulating the special metabolite lithocholyltaurine, thereby suppressing formation of KYSE450 tumors.This article has not yet been cited by other publications.

chemistry, multidisciplinary
Integrated proteomics and phosphoproteomics analyses of esophageal cancer cells with different invasive abilities

Nansong Xu,Changchun Lai,Qing-Mei He,Yubo Cai,Hui Yu,Wenhao Zhong,Shulin Chen,Fang-Cai Wu,Hao Chen

DOI: https://doi.org/10.1016/j.lfs.2023.122078

IF: 6.78

2023-09-21

Life Sciences

Abstract:Aims Esophageal squamous cell carcinoma (ESCC) is one of the aggressive and lethal malignancies with an extremely poor prognosis. It is necessary to explore the molecular mechanisms of ESCC invasion. Main methods We utilized high-throughput mass spectrometry to analyze the proteomes and phosphorylation profiles of two ESCC cell lines with differing invasion capacities (HK vs TE10). Differentially expressed proteins and phosphorites were identified, followed by comprehensive bioinformatics analyses encompassing function and pathway enrichment, protein-protein interaction (PPI) network analysis, hub gene identification, co-expression analysis, kinase-substrate prediction, and drug-target network analysis. CCK-8 assay, transwell examination, wound-healing assay, and western blot was used to validate the effects of fostamatinib on ESCC cells proliferation, invasion, migration, and LYN expression. Key findings The Q4 cluster of differentially phosphorylated proteins was primarily associated with functions and pathways relevant to tumor metastasis. Phosphorylated hub proteins including ARHGAP35, CTNNA1, and SHC1 were identified through the analysis of PPI network, and their respective regulated kinases were predicted. Among the predicted kinases, LYN was validated to be associated with lymph node metastasis (N0 vs. N1–3) and prognosis in ESCC patients at mRNA levels using TGGA data and protein levels in ESCC tissues ( p < 0.05). Validation experiments confirmed the inhibitory effects of fostamatinib on ESCC cells proliferation, migration, invasion, and LYN expression. Significance Our multi-omics analysis offers deeper perspectives on ESCC invasiveness and unveils new phosphorylated hub proteins with their regulatory kinase. This study also suggests that fostamatinib may be a potential agent for treating ESCC.

pharmacology & pharmacy,medicine, research & experimental
Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy

Zuozhang Yang,Zhenyi Su,Judy Park DeWitt,Lin Xie,Yongbin Chen,Xiaojuan Li,Lei Han,Dongqi Li,Junfeng Xia,Ya Zhang,Yihao Yang,Congguo Jin,Jing Zhang,Su Li,Kun Li,Zhiping Zhang,Xin Qu,Zewei He,Yanjin Chen,Yan Shen,Mingyan Ren,Zhongqin Yuan

DOI: https://doi.org/10.1016/j.ebiom.2017.04.017

IF: 11.205

EBioMedicine

Abstract:Bone is one of the most preferred sites of metastasis in lung cancer. Currently, bisphosphonates and denosumab are major agents for controlling tumor-associated skeletal-related events (SREs). However, both bisphosphonates and denosumab significantly increase the risk for jaw osteonecrosis. Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and the most frequently prescribed cholesterol-lowering agents, have been reported to inhibit tumor progression and induce autophagy in cancer cells. However, the effects of statin and role of autophagy by statin on bone metastasis are unknown. In this study, we report that fluvastatin effectively prevented lung adenocarcinoma bone metastasis in a nude mouse model. We further reveal that fluvastatin-induced anti-bone metastatic property was largely dependent on its ability to induce autophagy in lung adenocarcinoma cells. Atg5 or Atg7 deletion, or 3-methyadenine (3-MA) or Bafilomycin A1 (Baf A1) treatment prevented the fluvastatin-induced suppression of bone metastasis. Furthermore, we reveal that fluvastatin stimulation increased the nuclear p53 expression, and fluvastatin-induced autophagy and anti-bone metastatic activity were mostly dependent on p53.
Global and Targeted Metabolomics of Esophageal Squamous Cell Carcinoma Discovers Potential Diagnostic and Therapeutic Biomarkers*

Jing Xu,Yanhua Chen,Ruiping Zhang,Yongmei Song,Jianzhong Cao,Nan Bi,Jingbo Wang,Jiuming He,Jinfa Bai,Lijia Dong,Luhua Wang,Qimin Zhan,Zeper Abliz

DOI: https://doi.org/10.1074/mcp.m112.022830

IF: 7.381

2013-01-01

Molecular & Cellular Proteomics

Abstract:Diagnostic and therapeutic biomarkers useful for esophageal squamous cell carcinoma (ESCC) have the ability to increase the long term survival of cancer patients. A metabolomics study, using plasma from four groups including ESCC patients before, during, and after chemoradiotherapy (CRT) and healthy controls, was originally carried out by LC-MS to determine global alterations in the metabolic profiles and find biomarkers potentially applicable to diagnosis and monitoring treatment effects. It is worth pointing out that a clear clustering and separation of metabolic data from the four groups was observed, which indicated that disease status and treatment intervention resulted in specific metabolic perturbations in the patients. A series of metabolites were found to be significantly altered in ESCC patients versus healthy controls and in pre- versus post-treatment patients based on multivariate statistical data analysis (MVDA). To further validate the reliability of these potential biomarkers, an independent validation was performed by using the selected reaction monitoring (SRM) based targeted approach. Finally, 18 most significantly altered plasma metabolites in ESCC patients, relative to healthy controls, were tentatively identified as lysophosphatidylcholines (lysoPCs), fatty acids, l-carnitine, acylcarnitines, organic acids, and a sterol metabolite. The classification performance of these metabolites were analyzed by receiver operating characteristic (ROC)1 analysis and a biomarker panel was generated. Together, biological significance of these metabolites was discussed. Comparison between pre- and post-treatment patients generated 11 metabolites as potential therapeutic biomarkers that were tentatively identified as amino acids, acylcarnitines, and lysoPCs. Levels of three of these (octanoylcarnitine, lysoPC(16:1), and decanoylcarnitine) were closely correlated with treatment effect. Moreover, variation of these three potential biomarkers was investigated over the treatment course. The results suggest that these biomarkers may be useful in diagnosis, as well as in monitoring therapeutic responses and predicting outcomes of the ESCC.
Carfilzomib suppressed LDHA-mediated metabolic reprogramming by targeting ATF3 in esophageal squamous cell carcinoma

Lu Chen,Huanying Shi,WenXin Zhang,Yongjun Zhu,Haifei Chen,Zimei Wu,Huijie Qi,Jiafeng Liu,Mingkang Zhong,Xiaojin Shi,Tianxiao Wang,Qunyi Li

DOI: https://doi.org/10.1016/j.bcp.2023.115939

IF: 6.1

2023-11-24

Biochemical Pharmacology

Abstract:Carfilzomib, a second-generation proteasome inhibitor, has been approved as a treatment for relapsed and/or refractory multiple myeloma. Nevertheless, the molecular mechanism by which Carfilzomib inhibits esophageal squamous cell carcinoma (ESCC) progression largely remains to be determined. In the present study, we found that Carfilzomib demonstrated potent anti-tumor activity against esophageal squamous cell carcinoma both in vitro and in vivo . Mechanistically, carfilzomib triggers mitochondrial apoptosis and reprograms cellular metabolism in ESCC cells. Moreover, it has been identified that activating transcription factor 3 (ATF3) plays a crucial cellular target role in ESCC cells treated with Carfilzomib. Overexpression of ATF3 effectively antagonized the effects of carfilzomib on ESCC cell proliferation, apoptosis, and metabolic reprogramming. Furthermore, the ATF3 protein is specifically bound to lactate dehydrogenase A (LDHA) to effectively suppress LDHA-mediated metabolic reprogramming in response to carfilzomib treatment. Research conducted in xenograft models demonstrates that ATF3 mediates the anti-tumor activity of Carfilzomib. The examination of human esophageal squamous cell carcinoma indicated that ATF3 and LDHA have the potential to function as innovative targets for therapeutic intervention in the treatment of ESCC. Our findings demonstrate the novel function of Carfilzomib in modulating ESCC metabolism and progression, highlighting the potential of Carfilzomib as a promising therapeutic agent for the treatment of ESCC.

pharmacology & pharmacy
Association of Wild-Type TP53 with Downregulation of Lovastatin Sensitivity in Human Non-Small Cell Lung Cancer Cells

Yu-Yao Chang,Tsung-Ying Yang,Gwo-Tarng Sheu

DOI: https://doi.org/10.3390/cimb46090604

2024-09-13

Abstract:Statins inhibit 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway, and reduce cholesterol synthesis. They also have been demonstrated to improve prognosis in patients with various cancers, suggesting a potential anti-cancer effect of statins. However, there is no consensus on the molecular targets of statins for their anti-cancer effects. Docetaxel (DOC) is a microtubule-stabilizing agent currently used as a chemotherapeutic drug in several cancers, including lung cancer. Interestingly, the anti-cancer effects of either drug that are related to abnormal or wild-type TP53 gene have been implied. Therefore, the drug sensitivity of DOC and lovastatin in human lung cancer cells was evaluated. We found that H1355 (mutant TP53-E285K), CL1 (mutant TP53-R248W), and H1299 (TP53-null) human non-small cell lung cancer cells were more sensitive to lovastatin than A549 and H460 cells expressing wild-type TP53. Conversely, A549 and H460 cells showed higher sensitivity to DOC than H1299 and CL1 cells, as demonstrated by the MTT assay. When endogenous TP53 activity was inhibited by pifithrin-α in A549 and H460 cells, lovastatin sensitivities significantly increased, and cancer cell viabilities markedly reduced. These results indicate that TP53 status is associated with the anti-cancer effect of statins in human lung cancer cells. Mutated or null TP53 status is correlated with higher statin sensitivity. Furthermore, DOC-resistant H1299 (H1299/D8) cells showed significant sensitivity to lovastatin treatment compared to DOC-resistant A549 (A549/D16) cells, indicating a potential application of statins/chemotherapy combination therapy to control wild-type and abnormal TP53-containing human lung tumors.
Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis

Daniel F. Alonso,Hernán G. Farina,Guillermo Skilton,Mariano R. Gabri,Mariana S. De Lorenzo,Daniel E. Gomez

DOI: https://doi.org/10.1023/a:1006058409974

1998-07-01

Breast Cancer Research and Treatment

Abstract:Lovastatin, a fungal antibiotic used in the treatment of hypercholesterolemia, is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the key regulatory enzyme in the mevalonate pathway of cholesterol synthesis. We examined the antitumor properties of lovastatin on the F3II sarcomatoid mammary carcinoma, a highly invasive and metastatic murine tumor model. Female BALB/c inbred mice were inoculated subcutaneously with F3II tumor cells and injected i.p. daily with 10 mg/kg body weight of lovastatin or administered p.o. at a level corresponding to the human dosage of 1–2 mg/kg/day. Treatment significantly prolonged tumor latency and reduced tumor formation and metastatic dissemination to the lungs from established mammary tumors. In vitro, antitumor properties of lovastatin were strongly associated with inhibition of tumor cell attachment and migration. These actions were prevented by addition of mevalonate but not by equivalent concentrations of farnesyl pyrophosphate. In accordance, Western blot assays showed that lovastatin effects did not appear to be related to modifications in Ras oncoproteins in our model. The present data indicate that lovastatin could be an antitumor agent with potentially useful clinical applications in breast cancer.

oncology
Mechanism investigation of Forsythoside A against esophageal squamous cell carcinoma in vitro and in vivo

Yingying Yang,Junru Shen,Peiyuan Deng,Ping Chen

DOI: https://doi.org/10.1080/15384047.2024.2380023

2024-12-31

Abstract:Context: Forsythoside A (FSA) was extracted from Forsythia suspensa, a traditional Chinese medicine, which has been demonstrated to exert anti-inflammatory, antibacterial, and other pharmacological effects. However, the anticancer effect of FSA in esophageal squamous cell carcinoma (ESCC) has not been documented. Objective: The present study aimed to elucidate the mechanism of FSA against ESCC. Materials and methods: Network pharmacology and molecular docking were employed to predict the mechanism. FSA was utilized to treat ESCC cell lines KYSE450 and KYSE30, followed by CCK-8 assay, cell cloning formation assay, flow cytometry, Western blot, RNA-seq analysis, and subsequent in vivo experiments. Results: Network pharmacology and molecular docking predicted that the therapeutic effect of FSA in ESCC is mediated through proteins such as BCL2 and BAX, influencing KEGG pathways associated with apoptosis. In vitro experiments showed that FSA inhibited cell proliferation and plate clone formation, promoted cell apoptosis and impacted the cell cycle distribution of G2/M phase by regulating BCL2, BAX, and p21. Further RNA-seq in KYSE450 cells showed that FSA regulated the expression of 223 genes, specifically affecting the biological process of epidermal development. In vivo experiments showed that gastric administration of FSA resulted in notable reductions in both tumor volume and weight by regulating BCL2, BAX, and p21. 16S rRNA sequencing showed that FSA led to significant changes of beta diversity. Abundance of 11 specific bacterial taxa were considerably changed following administration of FSA. Conclusions: This study presents a novel candidate drug against ESCC and establishes a foundation for future clinical application.
Mefloquine Inhibited Esophageal Squamous Cells Carcinoma Proliferation by Induction of Mitochondrial Autophagy

Yifei Xie,Jing Zhang,Jimin Zhao,Xianyu Lu,Yaxing Wei,Bo Li,Zhuo Bao,Qiang Yuan,Xinhuan Chen,Zigang Dong,Kangdong Liu

DOI: https://doi.org/10.2139/ssrn.3429885

2019-01-01

SSRN Electronic Journal

Abstract:Background: Esophageal squamous cell carcinoma (ESCC) still has high rates of incidence and mortality, despite developments in medical technology. Therefore, looking for cancer treatment drugs with high efficiency and low toxicity remains very important. In the previous study, we screened FDA-approved drugs, approved for uses other than tumor treatment, and found that mefloquine (MQ), which is used for prevention and treatment of malaria, inhibited clone formation of ESCC cells.Methods: Proteomics and mass spectrometry (MS) were applied to profile proteome changes in ESCC cells after MQ treatment. KEGG was performed to analyse the significantly down-regulated pathways and proteins. Electron microscopy was used to observe mitochondrial changes in MQ-treated KYSE150 cells. And patient derived xenograft (PDX) mouse model was used to observe the anti-tumor effect of MQ in vivo.Findings: MS analyse showed that various proteins changed in MQ-treated KYSE150 cells. KEGG analyse identified dysregulated pathways and proteins. Among these proteins, SDHC, SDHD, MTCO3 and NDUFV3, all known to be essential enzymes in the mitochondrial respiration chain, were involved in these pathways and were notably down-regulated in MQ-treated cells. Meanwhile, mitochondrial autophagy was verified in MQ-treated cells by electron microscopy. Furthermore, MQ significantly inhibited tumor growth in a patient-derived xenograft mouse model of ESCC. All considered, MQ suppressed ESCC cell proliferation by induction of mitochondrial autophagy.Interpretation: Our data suggested that MQ may be a promising drug for ESCC treatment and chemoprevention.Funding Statement: This work was supported by grants from the National Natural Science Foundations of China (No. 81872335, 81572812, and 81472324) and the Natural Science Foundations of Henan (No. 161100510300).Declaration of Interests: The authors declare no conflicts of interest.Ethics Approval Statement: All procedures involving animals in this study were approved by the Animal Ethics Committee.
Tissue-based Metabolomics Reveals Metabolic Biomarkers and Potential Therapeutic Targets for Esophageal Squamous Cell Carcinoma

Zhongjian Chen,Yun Gao,Xiancong Huang,Yao,Keke Chen,Su Zeng,Weimin Mao

DOI: https://doi.org/10.1016/j.jpba.2021.113937

IF: 3.571

2021-01-01

Journal of Pharmaceutical and Biomedical Analysis

Abstract:Prognosis for esophageal squamous cell carcinoma (ESCC) is poor, so it is essential to develop a more complete understanding of the disease. The purpose of this study was to explore metabolic biomarkers and potential therapeutic targets for ESCC. An ultra-high-performance liquid chromatography coupled with high resolution mass (UPLC/MS)-based metabolomic analysis was performed in 141 ESCC cancerous tissue samples and 70 non-cancerous counterparts. The results showed that 41 differential metabolites were annotated in the training set, and 37 were validated in the test set. Single-metabolite-based receiver operating characteristic (ROC) curves as well as metabolite-based machine learning models, including Partial Least Squares (PLS), Support Vector Machine (SVM), and Random Forest (RF), were investigated for cancerous and non-cancerous tissue classification. Six most prevalent diagnostic metabolites—adenylsuccinic acid, UDP-GalNAc, maleylacetoacetic acid, hydroxyphenylacetylglycine, galactose, and kynurenine—showed testing predictive accuracies of 0.89, 0.95, 0.97, 0.89, 0.84, and 0.84, respectively. Moreover, the metabolite-based models (PLS, SVM, and RF) had testing predictive accuracies of 0.95, 0.95, and 1.00, respectively. Kaplan–Meier survival analysis and Cox proportional hazards regression analysis demonstrated that 2-hydroxymyristoylcarnitine (HR: 0.55, 95 % CI: 0.32 to 0.92), 3-hydroxyhexadecanoylcarnitine (HR: 0.49, 95 % CI: 0.29 to 0.83), and 2,3-Dinor-TXB1 (HR: 0.56, 95 % CI: 0.33 to 0.95) to be significantly associated with OS. Based on the observation of accumulation in amino acids, immunohistochemistry (IHC) staining revealed that the amino acid transporters SLC7A5/LAT1, SLC1A5/ASCT2, and SLC16A10/MCT10 were up-regulated in ESCC cancerous tissues when compared to non-cancerous equivalents. Consistently, the same panel of amino acids were downregulated in cells with SLC1A5 knockdown. Herein, it is concluded that this study not only identified several metabolites with diagnostic and/or prognostic value, but also provided accurate metabolite-based prediction models for ESCC tissue classification. Furthermore, the three up-regulated amino acid transporters were identified as potential therapeutic targets for ESCC, especially SLC1A5.
The Effects of an Incisal Bite Plane on Rat Sublingual Glands

S. Hioki,K. Niwa,T. Kishimoto,T. Kawazoe,Y. Yokota,K. Abe,C. Dawes

DOI: https://doi.org/10.1177/00220345830620060501

1983-06-01

Abstract:Application of an incisal bite plane for as little as three d caused a significant increase in the size of the sublingual glands of rats, with some evidence of hyperplasia and hypertrophy of the acinar cells. The enlargement had few effeets on salivary secretion, and the gland changes were reversible.
Celastrol Inhibited Human Esophageal Cancer by Activating DR5-Dependent Extrinsic and Noxa/Bim-Dependent Intrinsic Apoptosis

Xihui Chen,Shiwen Wang,Li Zhang,Shuying Yuan,Tong Xu,Feng Zhu,Yanmei Zhang,Lijun Jia

DOI: https://doi.org/10.3389/fphar.2022.873166

IF: 5.6

2022-06-09

Frontiers in Pharmacology

Abstract:Esophageal squamous cell carcinoma (ESCC) is one of the deadliest digestive system cancers worldwide lacking effective therapeutic strategies. Recently, it has been found that the natural product celastrol plays an anti-cancer role in several human cancers by inducing cell cycle arrest and apoptosis. However, it remains elusive whether and how celastrol suppresses tumor growth of ESCC. In the present study, for the first time, we demonstrated that celastrol triggered both extrinsic and intrinsic apoptosis pathways to diminish the tumor growth of ESCC in vivo and in vitro . Mechanistic studies revealed that celastrol coordinatively induced DR5-dependent extrinsic apoptosis and Noxa-dependent intrinsic apoptosis through transcriptional activation of ATF4 in ESCC cells. Furthermore, we found that the FoxO3a-Bim pathway was involved in the intrinsic apoptosis of ESCC cells induced by celastrol. Our study elucidated the tumor-suppressive efficacy of celastrol on ESCC and revealed a previously unknown mechanism underlying celastrol-induced apoptosis, highlighting celastrol as a promising apoptosis-inducing therapeutic strategy for ESCC.

pharmacology & pharmacy
Simvastatin induces breast cancer cell death through oxidative stress up-regulating miR-140-5p

Fuliang Bai,Ze Yu,Xin Gao,Jiawei Gong,Lizhi Fan,Feifei Liu

DOI: https://doi.org/10.18632/aging.101974

2019-05-28

Abstract:Statins, a class of hyperlipidemic drugs, are widely used cholesterol lowering drugs that selectively inhibit 3-hydroxy-3-methylglutaryl CoA reductase, which is the rate-limiting enzyme in cholesterol biosynthesis, leading to decreasing of cholesterol biosynthesis. Statins exert anti-tumoral effects on various cancer, including breast cancer. However, the molecular mechanisms for the actions were not fully elucidated. The purpose of this study was to elucidate the effects of statins on proliferation and apoptosis in the ER-negative breast cancer cell line MDA-MB-231. Our results showed that simvastatin increased the expression of miR-140-5p in a dose dependent manner via activating transcription factor NRF1, reduced cell proliferation and induced apoptosis, and we also found that SLC2A1 was a new target of miR-140-5p. In conclusion, data in this study shed light on the potential anti-tumoral effects of simvastatin in breast cancer and presents a highly promising therapeutic option, using drug and miRNA for combined treating cancers.

An interactive Whistle-to-Music composing system based on transcription, variation and chords generation

Proteome and phosphoproteome reveal mechanisms of action of atorvastatin against esophageal squamous cell carcinoma

Cloperastine inhibits esophageal squamous cell carcinoma proliferation in vivo and in vitro by suppressing mitochondrial oxidative phosphorylation

Proteomics Reveal the Inhibitory Mechanism of Levodopa Against Esophageal Squamous Cell Carcinoma

Lovastatin-mediated Pharmacological Inhibition of Formin Protein DIAPH1 Suppresses Tumor Immune Escape and Boosts Immunotherapy Response

Protection of Functional and Vascular Integrity of the Spleen in Traumatic Shock by Denervation.∗

Metformin Inhibited Esophageal Squamous Cell Carcinoma Proliferation in Vitro and in Vivo and Enhanced the Anti-Cancer Effect of Cisplatin

Dysregulated Ribosome Biogenesis is a Targetable Vulnerability in Triple-Negative Breast Cancer: MRPS27 As a Key Mediator of the Stemness-inhibitory Effect of Lovastatin

The Combination of Two Bioactive Constituents, Lactoferrin and Linolenic Acid, Inhibits Mouse Xenograft Esophageal Tumor Growth by Downregulating Lithocholyltaurine and Inhibiting the JAK2/STAT3-Related Pathway

Integrated proteomics and phosphoproteomics analyses of esophageal cancer cells with different invasive abilities

Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy

Global and Targeted Metabolomics of Esophageal Squamous Cell Carcinoma Discovers Potential Diagnostic and Therapeutic Biomarkers*

Carfilzomib suppressed LDHA-mediated metabolic reprogramming by targeting ATF3 in esophageal squamous cell carcinoma

Association of Wild-Type TP53 with Downregulation of Lovastatin Sensitivity in Human Non-Small Cell Lung Cancer Cells

Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis

Mechanism investigation of Forsythoside A against esophageal squamous cell carcinoma in vitro and in vivo

Mefloquine Inhibited Esophageal Squamous Cells Carcinoma Proliferation by Induction of Mitochondrial Autophagy

Tissue-based Metabolomics Reveals Metabolic Biomarkers and Potential Therapeutic Targets for Esophageal Squamous Cell Carcinoma

The Effects of an Incisal Bite Plane on Rat Sublingual Glands

Celastrol Inhibited Human Esophageal Cancer by Activating DR5-Dependent Extrinsic and Noxa/Bim-Dependent Intrinsic Apoptosis

Simvastatin induces breast cancer cell death through oxidative stress up-regulating miR-140-5p